The short answer: Whether HIPEC (heated chemotherapy in the belly, often called garam chemo) helps depends most on three things: whether the surgeon can remove all visible cancer, how far the cancer has spread inside the belly, and whether you are fit for a long operation. The type of cancer and the timing also matter: in ovarian cancer, the best evidence is for HIPEC at interval surgery, after about three cycles of chemotherapy. HIPEC is not right for everyone and is not a guaranteed cure; read about HIPEC eligibility and treatment.
HIPEC outcomes also vary between centres. Knowing what determines success helps patients ask the right questions and choose the right team.
On this page
- 1. Completeness of cytoreduction (CC score)
- 2. Peritoneal Cancer Index (PCI) score
- 3. Surgeon and centre volume
- 4. Cancer type and histology
- 5. Patient fitness for major surgery
- 6. Chemotherapy agent and protocol
- 7. Multi-disciplinary team support
- 8. Timing in the treatment journey
- 9. Post-operative care quality
1. Completeness of cytoreduction (CC score)
The single most important factor: how much visible cancer is left at the end of the operation. CC-0 (no visible residual disease) and CC-1 (residual under 2.5mm) are associated with the best survival. CC-2 and CC-3 results predict poor outcomes. Surgeon experience directly impacts the ability to achieve CC-0/1.
2. Peritoneal Cancer Index (PCI) score
PCI scores extent of peritoneal disease across 13 abdominal regions. PCI under 20 has significantly better outcomes than PCI over 20. Patient selection based on PCI matters.
3. Surgeon and centre volume
Teams that perform cytoreductive surgery with HIPEC regularly tend to have fewer serious complications and better results than teams that do it only occasionally. Ask how many of these operations the team does each year and how often they remove all visible cancer.
4. Cancer type and histology
Pseudomyxoma peritonei and selected ovarian cancers have the most established benefit. Colorectal peritoneal disease has selective benefit. Mucinous cancers vary: low-grade pseudomyxoma is among the best-established uses, while high-grade mucinous and signet-ring cell cancers respond less well.
5. Patient fitness for major surgery
HIPEC + cytoreductive surgery is a major procedure. Age alone is not a barrier, but performance status, cardiac and pulmonary function, and nutritional state must support an operation that often lasts 8–14 hours.
6. Chemotherapy agent and protocol
Different agents (cisplatin, mitomycin-C, oxaliplatin, doxorubicin) are used for different cancers. Temperature (41-43°C) and duration (60-90 min) must be standardised to recognised protocols.
7. Multi-disciplinary team support
A HIPEC programme needs trained anaesthesia, intensive care, perfusion technology, and oncology pharmacy. A solo surgeon without team support is a warning sign.
8. Timing in the treatment journey
In ovarian cancer, the clearest evidence is for HIPEC at interval surgery, the operation done after about three cycles of chemotherapy (OVHIPEC-1 trial, 2018: median overall survival 45.7 vs 33.9 months). A benefit at upfront (surgery-first) operations has not been proven, and evidence for recurrent cancer is less clear: a 2025 review of eight trials found no clear survival benefit in recurrence. Timing is critical.
9. Post-operative care quality
Enhanced recovery protocols, prompt mobilisation, careful fluid management, and prevention of post-operative complications all affect outcomes. The first 7 days after HIPEC are crucial. Most patients stay in hospital about 10–14 days, including 3–5 days in intensive care; see preparation and recovery around HIPEC.
What to do next
For an honest, evidence-based assessment of whether HIPEC is appropriate for you and which centre is right, request a second opinion with Dr. Nishtha Tripathi Patel. WhatsApp your reports to +91 76988 00333.
HIPEC is only one part of ovarian cancer diagnosis and treatment; the team first decides the overall plan, including when surgery and chemotherapy should happen.
Related
External reference: Van Driel et al., NEJM HIPEC trial.
FAQs
What is the success rate of HIPEC surgery?
It depends on the cancer type, how much cancer can be removed and your fitness. In the main ovarian-cancer trial (OVHIPEC-1, surgery after chemotherapy), median overall survival was about 12 months longer with HIPEC (45.7 vs 33.9 months). Most women still needed further treatment later, so HIPEC is not a guaranteed cure.
Who is eligible for HIPEC?
Selected patients only: usually stage 3 (sometimes stage 4) ovarian cancer when all visible tumour can be removed and the patient is fit for a long operation. The decision is made by the specialist team after scans and tests.
What is a PCI score?
The Peritoneal Cancer Index (PCI) measures how much cancer has spread over the lining of the belly, scoring 13 regions. A lower score usually means it is more likely that all visible cancer can be removed.
What does CC-0 mean?
CC-0 means no visible cancer is left at the end of the operation. CC-1 means only very small spots (under 2.5 mm) remain. These results are linked with the best outcomes.
Can older women have HIPEC?
Age alone is not a barrier. What matters is overall fitness, heart and lung function and nutrition, because the operation often lasts 8–14 hours and is followed by about 10–14 days in hospital.
Reviewed by Dr. Nishtha Tripathi Patel, MBBS, DGO, DNB, Fellowship Gynaecological Oncology, ESGO-certified.